22.25
-1.26 (-5.34%)
| Previous Close | 23.50 |
| Open | 23.30 |
| Volume | 149,344 |
| Avg. Volume (3M) | 797,635 |
| Market Cap | 724,199,616 |
| Price / Earnings (TTM) | 17.52 |
| Price / Earnings (Forward) | 3.43 |
| Price / Sales | 1.01 |
| Price / Book | 2.34 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Profit Margin | 6.61% |
| Operating Margin (TTM) | 13.71% |
| Diluted EPS (TTM) | 1.22 |
| Quarterly Revenue Growth (YOY) | 22.70% |
| Quarterly Earnings Growth (YOY) | -91.30% |
| Total Debt/Equity (MRQ) | 411.94% |
| Current Ratio (MRQ) | 1.08 |
| Operating Cash Flow (TTM) | 198.44 M |
| Levered Free Cash Flow (TTM) | 341.32 M |
| Return on Assets (TTM) | 7.95% |
| Return on Equity (TTM) | 19.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Collegium Pharmaceutical, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Relative Valuation | -5.0 |
| Financial Health | 2.5 |
| AI Insight | NA |
| Weighted Average | 1.06 |
Select this tab to load the latest available analysis.
|
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.69% |
| % Held by Institutions | 117.12% |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |